The Czech Rheumatological Society recommendations for monitoring the treatment safety in rheumatoid arthritis
Authors:
L. Šedová 1; J. Štolfa 1; P. Horák 2; K. Pavelka 1
Authors‘ workplace:
Revmatologický ústav, Praha, 2III. interní klinika FN a LF UP Olomouc
1
Published in:
Čes. Revmatol., 17, 2009, No. 1, p. 4-9.
Category:
Original Papers
Overview
The report follows the Czech Rheumatological Society recommendations for the treatment of rheumatoid arthritis, which deal with the strategy and efficacy of treatment approaches. Herein, we deal with ways of monitoring the treatment safety with agents from the DMARDs group (disease modifying antirheumatic drugs), as well as nonsteroidal anti-inflammatory drugs. The report is divided according to particular agents. In DMARDs, their main toxicity is stated, in nonsteroidal anti-inflammatory drugs, the gastrointestinal, cardiovascular, renal and other toxicity is analysed with special notes to coxibs. The necessary tests prior to the start of treatment and regular periodic follow-ups during the treatment are listed. Notes to pregnancy, lactation and basic vaccinations are presented, as well. In the last part, the pre-operative preparation of patients with rheumatoid arthritis is mentioned.
Key words:
treatment safety in rheumatoid arthritis, toxicity of DMARDs, NSAIDs, pregnancy, lactation, pre-operative preparation
Sources
1. Kwek TK, Lew TW, Thoo FL. The role of preoperative cervical spine X-rays in rheumatoid arthritis. Anaesth Intensive Care 1998; 26: 636-41.
2. Mulroy WF, Estoks DM, Harris WH. Total hip arthroplasty with use of so-called second generation cementing techniques. Joint Surg Am 1995; 77: 1845-52.
3. Wymenga AB, van Horn JR, Theeuwes A, Muytjens HL, Slooff TJ. Perioperative factors associated with septic arthritis after arthroplast. Prospective multicenter study of 362 knee and 2651 hip operations. Acta Orthop Scand 1992; 63: 665-71.
4. Lehman DE, Capello WN, Feinberg JR. Total hip arthroplasty without cement in obese patients. A minimum two-year clinical and radiographic follow-up study. J Bone Joint Surg Am 1994; 76: 854-62.
5. Eijsbouts A, van den Hoogen F, Laan R, et al. Similar response of adrenocorticotrhophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1998; 37: 1138-9.
6. Friedman RJ, Schiff CF, Bromberg JS. Use of supplemental steroids in patients having orthopedic operations. J Bone Joint Surg Am 1995; 77: 1801-6.
7. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287: 236-40.
8. Buckwalter JA, Ballard WT, Brooks P. Principles of arthritis surgery. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology 3rd edition. New York: Mosby; 2003. p. 532-542.
9. Wilke WS, Clough JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not trteated with methotrexate. Arthritis Rheum 1991; 34: 146-52.
10. Sany J, Anaya JM, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20: 1129-32.
11. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Ann Rheum Dis 2001; 61: 86-7.
12. Rosandich PA, Kelley JT 3rd, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004; 16: 192-8.
13. Schreiber S, Campieri M, Colombel JF. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001; 16; 1-11; discussion 12-3.
14. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004; 25: 331-5.
15. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005; 64: 650-1.
16. Wendling D, Balblanc JC, Brousse A, et al. Surgery in patients receiving anti tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study of 50 surgical procedures. Ann Rheum Dis 2005; 64, 1378-9.
17. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55: 333-7.
18. Jain A, Maini R, Nanchahal J. Disease modifying treatment and elective surgery in rheumatoid arthritis: need for more data. Ann Rheum Dis 2004; 63, 602-3.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2009 Issue 1
Most read in this issue
- Interleukin 6 in rheumatic diseases
- News in the biological therapy of rheumatoid arthritis and future prospects
- Rituximab in the treatment of Wegener’s granulomatosis non-responsive to standard therapy
- Collagen and elastin degradation products as potential activity markers of scleroderma